We audited whether 18 F-Fluorodeoxyglucose positron emission tomography-computed tomography ( 18 FDG PET-CT) imaging could discriminate between different diagnoses in HIV-infected patients presenting with lymphadenopathy, with or without fever and/or splenomegaly. Maximum standardised uptake (SUV max ) values were similar in lymphoma and mycobacterial and fungal infections and were lower but similar in those with human herpesvirus (HHV) 8-associated disease and HIV-associated reactive lymphadenopathy. Nodal 18 FDG avidity, with SUV max 10, excluded diagnoses of HHV 8-associated disease and miscellaneous conditions, and HIV-associated reactive lymphadenopathy was additionally excluded in those who had undetectable plasma HIV viral loads. This audit suggests 18 FDG PET-CT imaging did not permit discrimination between specific diagnoses but has utility in identifying lymph nodes with increased avidity that could be targeted for biopsy and in ruling out significant pathology.
Introduction
The immunosuppressed HIV-infected patient can present with lymphadenopathy, with or without a fever and/or splenomegaly. 1 The differential diagnosis for this presentation is wide and includes Hodgkin and non-Hodgkin lymphoma, human herpesvirus 8 (HHV 8)-associated disease, including Kaposi sarcoma (KS) and multicentric Castleman disease (MCD), Mycobacterium tuberculosis, disseminated Mycobacterium avium complex, leishmaniasis and histoplasmosis, [1] [2] [3] as well as other conditions such as metastatic carcinoma and HIV-associated 'reactive' lymphadenopathy. Definitive diagnosis often requires tissue sampling with histology and/or microbiological culture in addition to traditional investigations. FDG PET-CT imaging, CD4 cell count, plasma HIV load and whether the patient was receiving antiretroviral therapy (ART) at the time of diagnosis. The diagnosis of lymphoma, HHV 8-associated disease and HIV-associated reactive lymphadenopathy was made histologically, while that of mycobacterial and fungal infections was made by microbiological culture, as previously described. 12 In each patient, 18 FDG PET-CT scanning was done prior to tissue sampling, and before the results of microbiological culture were available. Patients in whom a tissue diagnosis of malignancy had been made and who subsequently underwent 18 FDG PET-CT scanning for staging were excluded, as were those with undifferentiated fever, or pyrexia of undetermined origin (PUO). Results were analysed using Mann-Whitney and Kruskal-Wallis tests to compare SUV max values among different patient groups. GraphPad Prism Version 6.0h (GraphPad software, Inc., La Jolla, CA, USA) was used for statistical analysis; p <0.05 was regarded as statistically significant.
Results
A total of 120 patients (88 men) presented with lymphadenopathy, with or without fever and/or splenomegaly and underwent 18 FDG PET-CT. Figure 1 The final diagnosis was HIV-related reactive lymphadenopathy in 43 patients, lymphoma in 27 (Hodgkin lymphoma in 13, diffuse large B-cell in 7, Burkitt in 3, plasmablastic in 3 and T-cell in 1), HHV 8-associated disease in 19 (KS in 5, MCD in 7 and KS with MCD in 7), mycobacterial infection in 14 (M. tuberculosis in 8, M. avium complex in 6) and fungal infections in 4 (Cryptococcus neoformans in 3, histoplasmosis in 1). Thirteen patients had a wide range of miscellaneous conditions: these were adult-onset Still's disease, sclerosing peritonitis, intra-abdominal sepsis, metastatic adenocarcinoma, reflux oesophagitis/benign colonic polyp, lobar pneumonia, visceral leishmaniasis, necrotizing granulomatosis, nodular hepatic fibrosis secondary to schistosomiasis, toxoplasmosis, and nodular hepatic fibrosis/portal hypertension with thyrotoxicosis/thyroiditis, each in one patient, and self-limiting febrile episodes with lymphadenopathy in two patients.
SUV max values were similar in lymphoma and mycobacterial and fungal infections and were lower but similar in those with HHV 8-associated disease and HIV-associated reactive lymphadenopathy. Individuals with miscellaneous (largely non-infectious and non-malignant conditions) had low SUV max values (Table 1) . Across all diagnoses, there were statistically significant differences in median SUV max when lymphoma was compared with HIV-associated reactive lymphadenopathy (p ¼ 0.0007) and with HHV 8-associated diseases (p ¼ 0.0008) and when mycobacterial infection was compared with HIV reactive and HHV 8-associated diseases (p ¼ 0.004 and p < 0.0001, respectively). No statistically significant differences were found between the other groups of diagnoses. Within each diagnostic group, median SUV max showed no significant differences in those with detectable and those with undetectable viral loads ( Table 1) . Among all patients, nodal FDG avidity, with SUV max 10, excluded diagnoses of HHV 8-associated disease and miscellaneous conditions, and HIV-associated reactive lymphadenopathy was additionally excluded in those in receipt of ART who had undetectable plasma viral loads. Reversal of the liver:spleen 18 FDG avidity ratio was observed more commonly among those with detectable viral loads but did not aid discrimination between diagnoses.
Discussion
This audit shows similar avidity of 18 FDG uptake, measured by SUV max , in patients with lymphoma, mycobacterial infection and fungal infection; accordingly, 18 FDG-PET-CT imaging did not provide diagnostic information enabling discrimination between these diagnoses. A SUV max 10 enabled HHV 8-associated disease and miscellaneous conditions to be excluded in all patients, and additionally, in those in receipt of ART who had undetectable plasma viral loads HIVassociated reactive lymphadenopathy could be excluded.
This observation requires validation in prospective studies before it is used in diagnostic algorithms. In HIV-infected patients, different pathology may occur concurrently. This audit did not identify any features on 18 FDG PET-CT imaging that suggested coexistence of dual or multiple pathology. The utility of 18 FDG PET-CT imaging was in identifying lymph nodes with increased avidity that could be targeted for biopsy and in excluding significant pathology. The limitations of this audit are first, it is from a single centre and second, the sample size is small. Additionally, patients with undifferentiated PUO, and those with an established tissue diagnosis of malignancy prior to 18 FDG PET-CT scanning were excluded. 
